Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRAPLO haplo-identical transplantation in myelofibrosis
2024-513325-23-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in myelofibrosis (MF), primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Disease- and rejection-free survival at 12 months after HSCT. Planned start Jul 2024; status: authorised.
02
Drugs
treosulfan
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on 2024-513325-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513325-23-00.